Updated information about Biomarin's BMN-111 clinical development

Biomarin has updated its website, posting more detailed information regarding the clinical development of BMN-111, a CNP analogue, the first potential pharmacological therapy for achondroplasia reaching clinical trials. 

For more details, you can visit: http://www.biomarinclinicaltrials.com/Achondroplasia.html.

You can learn more about CNP reading this previous article published in the blog:

http://tratando-acondroplasia.blogspot.com/2012/02/first-potential-pharmacological-therapy.html.